Login / Signup

Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.

Gunjan L ShahJaap Jan BoelensDean CarlowAndrew LinRyan SchofieldNancy Cruz SitnerAnna AlperovichJosel RuizAnthony ProliParastoo DahiRoni TamariSergio A GiraltMichael ScordoRick Admiraal
Published in: Clinical pharmacokinetics (2021)
The proposed model adequately describes the population pharmacokinetics of melphalan in adult patients receiving a hematopoietic cell transplantation. This model can be used to define the therapeutic window of melphalan, and subsequently to develop individualized dosing regimens aiming for that therapeutic window in all patients.
Keyphrases
  • high dose
  • stem cell transplantation
  • end stage renal disease
  • bone marrow
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • patient reported outcomes
  • kidney transplantation
  • mesenchymal stem cells